Board Change
Oxford, UK – 27 January 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces a change to the Group’s Board of…
Oxford Biomedica to Present at 41st Annual J.P Morgan Healthcare Conference
Oxford, UK – 21 December 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer, will…
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
Agreements signed with three new partners, bringing the total number of new AAV customers in 2022 to four, ahead of original target Oxford, UK – 14 December 2022: Oxford Biomedica plc…
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
Oxford, UK – 22 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as…
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces exchange of contracts for the sale…
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…
Interim results for the six months ended 30 June 2022
Significant strategic and operational progress towards becoming a global viral vector leader Oxford, UK – 15 September 2022: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading…
Oxford Biomedica Solutions signs agreement with new partner for AAV platform
Oxford, UK – 14 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions…
Oxford Biomedica signs Licence & Supply Agreement with new partner for LentiVector® platform for late-stage clinical programme
Oxford, UK – 7 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new…
Oxford Biomedica notes Homology Medicines’ quarterly report and confirms financials for Oxford Biomedica Solutions LLC are in line with expectations
Oxford, UK – 16 August 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the release of Homology Medicines’ (“Homology”) quarterly…
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has signed a new Licence…
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new…